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AIMS
Adverse drug reactions (ADRs) contribute to poorer patient outcomes and additional burden to the healthcare system. However,
data on the true burden, relevant types and drugs causing ADRs are lacking. The aim of this study was to determine the prevalence
of ADR-related hospitalization in the general adult population in Singapore and to investigate their characteristics.
METHODS
We prospectively recruited 1000 adult patients with unplanned admission to a large tertiary-care hospital. Two independent re-
viewers evaluated all suspected ADRs for causality, type, severity and avoidability. The prevalence of ADR-related hospitalization
was calculated based on ‘definite’ and ‘probable’ ADRs. Logistic regression was used to evaluate predictors for having an ADR at
admission.
RESULTS
The prevalence of all ADRs at admission was 12.4% (95% CI: 10.5–14.6%) and ADRs causing admission was 8.1% (95% CI:
6.5–10.0%). The most common ADRs were gastrointestinal-related. The most common drug category causing ADRs were
cardiovascular drugs. Patients with ADRs had a longer length of stay than those who did not (median 4 vs. 3 days, P = 1.70 × 103).
About 30% of ADRs at admission were caused by at least one drug with a clinical annotation in the Pharmacogenomics
KnowledgeBase (PharmGKB), suggesting that some of these ADRs may have been predicted by pharmacogenetic testing.
CONCLUSIONS
We have quantified the burden and characteristics of clinically impactful ADRs in the Singaporean general adult population. Our
results will provide vital information for efforts in reducing ADRs through targeted vigilance, patient education and
pharmacogenomics in Singapore.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Adverse drug reactions (ADRs) contribute to adverse clinical outcomes and add to healthcare costs
• The true burden and their characteristics in adult Singaporeans are unknown.
WHAT THIS STUDY ADDS
• The prevalence of ADRs at admission in Singaporean adults was 12.4% and that causing admission was 8.1%.
• Patients with ADRs have a longer length of stay than those who do not.
• The most common ADRs were gastrointestinal ADRs and most common drugs causing ADRs were cardiovascular drugs.
Introduction
Adverse drug reactions (ADRs) are a major cause of morbidity
and mortality, and leading cause of hospital admission [1].
ADRs negatively affect patients’ quality of life and confidence
inmedications, which consequently leads to worse treatment
outcomes [2]. A major limitation in ADR research is that we
lack reliable data on the true prevalence and burden of ADRs.
This relates to the fact that information about ADRs is tradi-
tionally captured through voluntary reporting systems,
which vastly under-report the true number of ADRs [3], and
do not capture information about the number of patients at
risk, making assessment of the relative frequencies of differ-
ent ADRs impossible. Singapore has one of the highest per
capita rates of spontaneous ADR reporting in the world [4],
but nonetheless, under-reporting, incomplete information
and reporting bias lead to an inability to calculate the true
prevalence of ADRs [3]. Understanding the healthcare burden
of ADRs as well as the relevant types and drugs involved rep-
resents an important gap in our knowledge.
Studies based on medical records review in the UK and
other countries have reported that the prevalence of hospital
admissions caused by ADRs range from 2.3 to 21.2%, and that
a substantial proportion of these ADRs are potentially pre-
ventable [5–14]. In Singapore, similar studies have been con-
ducted in the paediatric population (2.6%) [15], patients on
polypharmacy (2.3%) [16] and oncology patients (12.2%)
[17]. However, data from the general adult population in
Singapore or other Asian countries are lacking.
Pharmacogenomic markers have been identified for a
growing number of drugs for serious ADRs, and implementa-
tion of pharmacogenomic testing has been advanced as a
means to prevent the occurrence of some of these ADRs. A
notable example is the recommendation for pharmacoge-
netic testing of HLA-B*1502 allele prior to the prescription
of carbamazepine as risk stratification for the prevention of
severe skin allergic reactions in Singapore and Taiwan, lead-
ing to a significant drop in cases of carbamazepine-induced
Stevens-Johnsons syndrome and toxic epidermal necrolysis
(SJS/TENS) [18, 19]. Examining ADRs for association with
pharmacogenomic markers would provide an additional
layer of information on the potential preventability of these
ADRs.
To address these gaps in knowledge, we undertook a
prospective observational study of ADRs occurring among
patients at the time of admission to a large tertiary care hospi-
tal in Singapore. The key objectives of this study were to
determine the prevalence, specific types and characteristics
of ADRs that occur among patients at the time of admission
to hospital, and to explore the role of pharmacogenomic
markers associated with these ADRs.
Methods
We prospectively recruited 1000 patients admitted to
Singapore General Hospital (SGH), a 1600-bed tertiary teach-
ing hospital, from December 2015 to February 2016 by ran-
domly selecting 20 patients every weekday from patients
admitted the preceding day. This was done by selecting the
patients with the 20 smallest random numbers generated
against their names using Excel RAND() function in a list
based on admission date in which patients discharged on
the same day were also included. Elective admissions, obstet-
ric cases, patients aged <21 years old and patients directly
transferred from other hospitals were excluded. The sample
size of 1000 was expected to allow us to estimate the preva-
lence with 95% confidence interval (CI) of 4.6–7.7%, based
on the reported prevalence of 6% from a large UK study [5].
This study was approved by the ethics review committee of
SGH with waiver of informed consent.
A trained pharmacist recorded clinical information for
the selected patients each day from electronic medical re-
cords and case notes, and cumulatively for all 1000 patients
throughout the study period. Information collected include
demographics, presenting complaints, past medical history,
all drugs taken in the preceding 2 weeks (or 1 month for che-
motherapeutic drugs), preliminary and final diagnoses,
length of stay and mortality. If any information was incom-
plete at the time of admission, the patient was followed up
until all information required was collected.
The same pharmacist assessed whether an ADR was pres-
ent at the point of admission by matching the presenting
complaints and findings to ADR profiles of drugs the patient
was taking, using Lexi-Comp [20] and Micromedex [21] as
drug references.We used the Edwards and Aronson definition
of ADR: ‘an appreciably harmful or unpleasant reaction,
resulting froman intervention related to theuseof amedicinal
product, which predicts hazard from future administration
and warrants prevention or specific treatment, or alteration
of the dosage regimen, or withdrawal of the product’ [22]. All
suspected ADRs present at admission, whether or not they
were the main reason for hospital admission, were captured.
We excluded ADRs due to drug abuse, complementary
alternative medicines or intentional poisoning as they are
not amenable to the systematic clinical studies needed to in-
vestigate genetic factors modifying drug response. If an ADR
was suspected, more details were recorded and each suspected
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ADR–drug(s) pair was further assessed for causality using the
Liverpool Causality Assessment Tool (LCAT) [23], type, using
the classification of Rawlins and Thompson [24] (type A: dose
dependent and predictable from the known pharmacology of
the drug, and type B: not dose dependent and unpredictable),
severity, using the adapted Hartwig scale [25] (Table S1) and
avoidability, using the Method of Hallas et al. [26] (Table S2).
The causality, type, severity and avoidability for each
suspected ADR–drug(s) pair were assessed independently by
a second study teammember, and any disagreements were re-
solved by a third member by consensus. Both the second and
third teammembers were also trained pharmacists. To ensure
accurate classificationandcompleteness, data entered for 10%
of admissions deemed not to be ADR-related were randomly
sampled and reviewed by the second study teammember.
Statistical analysis
All data was entered into the Epi Info 7.1.5.2 software [27],
and the data subsequently exported and analysed in R ver-
sion 3.1.0 [28]. The prevalence of ADR-related hospitaliza-
tions was calculated based on ADRs with a consensus LCAT
causality rating of ‘definite’ or ‘probable’.
While all prescribed or received items in the 2 week (or 1
month for chemotherapeutic drugs) window prior to admis-
sion were recorded, certain categories were excluded (cos-
metic products, surgical products, nasal care, oral care and
eye care) and only the number of active ingredients in the re-
maining items were used for analysis. Combination products
were counted as one active ingredient unless each compo-
nent was also available as a product separately, according to
the database of registered medicinal products maintained by
the Health Sciences Authority of Singapore [29]. Drugs for
which the patient was known to be non-adherent to, based
on documentation in the medical records by a doctor or
pharmacist, were also excluded (<0.6% of all drug entries).
For ease of presentation, drugs were grouped into classes
using the Anatomical Therapeutic Chemical (ATC) classifica-
tion system [30]. Drugs were also annotated with respect to
whether they had a Pharmacogenomics Knowledgebase
(PharmGKB) clinical annotation (CA), and associated details
such as gene, level of evidence and type of outcome.
PharmGKB CAs are manually curated with levels of evidence
ranging from 1A (highest) to 4 (lowest) [31]. Each drug was
then further explored whether the ADRs were caused by
drugs with PharmGKB CAs for a matching phenotype.
Differences in length of stay and mortality between
patients with and without ADRs were tested using the
Mann-Whitney U and Fisher’s exact tests, respectively. Risk
factors for ADRs at admission were investigated using univar-
iate logistic regression. For multivariate analysis, possibly col-
linear variables among significant variables from univariate
analyses were first removed sequentially based on the vari-
ance inflation factor (VIF) (highest removed first), until all
are<1.5 [32]. The cut-off of 1.5 was arbitrary and took into ac-
count biological knowledge of the variables tested. The
remaining variables were then put through an Akaike
Information Criteria (AIC)-based stepwise logistic regression
to select the best set of predictors for having an ADR at admis-
sion (more details in Supplementary information). A P-value
of <0.05 was deemed statistically significant.
Results
Demographics
We studied 1000 patients admitted to hospital over a 3-
month period. The characteristics of these patients are shown
in Table 1. Most patients (78.5%) were admitted to medical
wards and 91.3% manifested at least one co-morbidity. The
median number of drugs prior to admission was seven (range
0–28). Two-thirds of all patients were taking five or more
drugs prior to admission.
Number and significance of ADRs
A total of 124 patients had at least one ‘definite’ or ‘probable’
ADR at the point of admission (12.4%, 95% CI: 10.5%–
14.6%). In 81 of these patients, the ADR was the cause of hos-
pital admission (8.1%, 95% CI: 6.5%–10.0%, or 65% of pa-
tients who experienced an ADR) (Table S3). To assess the
sensitivity of our ADR detection, we randomly selected
10% of all non-ADR cases to perform an additional quality
control assessment. Of these cases, we detected that one
patient had been misclassified, and we found no major
omission or inaccuracy of recorded information. Inter-rater
agreement between the two assessors on causality was
moderate (kappa = 0.544) and was within the range of
pairwise agreements in the testing of the LCAT tool
(0.51–0.85) [23].
A total of 135 ADRs occurred in these 124 patients. All but
two of these ADRs were type A (dose dependent and predict-
able from the known pharmacology of the drug). Most
(91.9%) had levels 1 to 3 severity and were possibly avoidable
(94.1%). Of the 11 ADRs (8.1%)with severity levels 4 to 6, four
involved bleeding due to warfarin or clopidogrel with level 4
severity. Four patients with ADRs died, and the cause of
death was related to the ADR(s) in two of these patients.
ADRs causing and occurring at admission were similar in
their causality, type and avoidability (Figure 1). However,
ADRs causing admission were more severe than those which
were not causative of admission (Fisher’s exact test P-value =
2.19 × 105) (Figure 1). A detailed breakdown of the number
of ADRs by causality, type, severity and avoidability is
shown in Table S3.
Patients with ADR(s) at admission had a significantly lon-
ger length of stay than those who did not experience an ADR
(median 4 days vs. 3 days, respectively, P-value = 1.70 × 103).
There was no statistically significant difference in mortality
rate between patients with or without ADRs (3.4% vs. 3.0%,
respectively, P = 0.781). Compared to patients without an
ADR on hospital admission, patients with an ADR were older
(OR = 1.02, 95% CI = 1.01–1.03), more likely to be medical
patients (OR = 2.56, 95%CI = 1.46–4.86), more likely to be ad-
mitted to oncology specialty (OR = 2.85, 95%CI = 1.69–4.69),
more likely to be admitted from specialist outpatient clinics
(OR = 2.47, 95% CI = 1.55–3.87), more likely to have a cardio-
vascular (CVS) condition (OR = 3.43, 95% CI = 2.07–6.02) or
cancer (OR = 2.23, 95% CI = 1.49–3.32). Patients with an
ADR also received more drugs before admission (OR = 1.08,
95% CI = 1.05–1.12), and were more likely to receive a drug
with PharmGKB CA with level 1 or 2 evidence (OR = 2.88,
95% CI = 1.76–5.00) (Table 1).
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Table 1
Patient characteristics and association with presence of ADR at admission
Characteristic All patients
ADR at
admission
(n = 124)
No ADR at
admission
(n = 876) OR (95% CI) P-value
Female gender, n (%) 474 (47.4) 59 (47.6) 415 (47.4) 1.01 (0.69–1.47) 0.966
Age, mean (SD) 62.8 (16.9) 67.1 (14.2) 62.1 (17.2) 1.02 (1.01–1.03) 2.51 × 103
Ethnicity, n (%)
Chinese 690 (69.0) 88 (71.0) 602 (68.7) Ref 0.512a
Malays 127 (12.7) 14 (11.3) 113 (12.9) 0.85 (0.45–1.50)
Indians 137 (13.7) 19 (15.3) 118 (13.5) 1.10 (0.63–1.84)
Others 46 (4.6) 3 (2.4) 43 (4.9) 0.48 (0.11–1.35)
Has drug allergy, n (%) 244 (24.4) 34 (27.4) 210 (24.0) 1.20 (0.78–1.81) 0.403
Ward type, n (%)
Surgical 215 (21.5) 13 (10.5) 202 (23.1) Ref
Medical 785 (78.5) 111 (89.5) 674 (76.1) 2.56 (1.46–4.86) 1.99 × 103
Oncology 92 (9.2) 24 (19.4) 68 (7.8) 2.85 (1.69–4.69) 5.57 × 105
Admitted from, n (%)
Emergency 865 (86.5) 93 (75.0) 772 (88.1) Ref
Specialist outpatient clinics 135 (13.5) 31 (25.0) 104 (83.9) 2.47 (1.55–3.87) 9.56 × 105
Co-morbidities, n (%) 913 (91.3)
CVS condition 674 (67.4) 107 (86.3) 567 (64.7) 3.43 (2.07–6.02) 5.19 × 106
Diabetes 319 (31.9) 45 (36.3) 274 (31.3) 1.25 (0.84–1.85) 0.263
Chronic kidney disease 183 (18.3) 24 (19.4) 159 (18.2) 1.08 (0.66–1.72) 0.746
Has cancer 223 (22.3) 45 (36.3) 178 (20.3) 2.23 (1.49–3.32) 8.68 × 105
No. of medications received, median (range) 7 (0–28) 9 (1–20) 7 (0–28) 1.08 (1.05–1.12) 4.48 × 106
Proportion of drugs with PharmKGB CA, median (range)
Any level of evidence 52.6 (0–100) 57.1 (0–100) 50.0 (0–100) 1.01 (1.01–1.02) 5.30 × 10-4
Level 1 only 0 (0–100) 7.7 (0–50) 0 (0–100) 1.01 (0.99–1.02) 0.346
Level 1 or 2 16.7 (0–100) 18.5 (0–75) 16.7 (0–100) 1.01 (1.00–1.02) 0.048
Have at least 1 drug with PharmGKB CA, n (%)
Any level of evidence 829 (82.9) 122 (98.4) 707 (80.7) 14.6 (4.58–88.9) 1.90 × 104
Level 1 only 460 (46.0) 73 (58.9) 387 (44.2) 1.81 (1.24–2.66) 2.34 × 103
Level 1 or 2 694 (69.4) 106 (85.5) 588 (67.1) 2.88 (1.76–5.00) 6.36 × 105
Outcomes
Length of stay (days), median (range) 3 (1–112)b 4 (1–44) 3 (1–112) NA 1.70 × 103c
Mortality rate, n (%) 30 (3.0)b 4 (3.2) 26 (3.0) NA 0.781d
P-values are logistic regression P values unless stated otherwise. Oncology (under medical ward type) indicates the patient had been admitted to the
specialty for the current admission, while ‘has cancer’ (under co-morbidities) indicate that the patient has ever had a cancer diagnosis. A CVS con-
dition includes at least one of the following: hypertension, hyperlipidaemia, congestive heart failure, history of myocardial infarction, ischemic heart
disease, rheumatic heart disease, atrial fibrillation, coronary artery disease and any arrhythmias
ADR, adverse drug reaction; CVS, cardiovascular; NA, not applicable; OR, odds ratio; PharmGKB CA, Pharmacogenomics knowledgebase clinical
annotation; Ref, reference; SD, standard deviation
aGlobal test of significance using Analysis of Variance
bCensored on 31 Mar 2016 with 3 patients still not discharged
cMann-Whitney U test
dFisher’s exact test
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Types of ADRs and drugs
The most common types of ADRs were gastrointestinal (GI)-
related, followed by electrolyte abnormalities and bleeding
and/or supratherapeutic International Normalized Ratio
(INR) (Figure 2 and Table S4). The most common ADR types
that were causative of hospital admission were GI and bleed-
ing and/or supratherapeutic INR (Figure 2). A substantial pro-
portion of electrolyte abnormalities and renal impairment
were detected at hospital admission but were not deemed to
be the cause of hospital admission.
The most common categories of drugs that cause ADRs
were CVS, followed by anti-coagulants/antiplatelets and che-
motherapeutic drugs (Figure 3 and Table S5). This was similar
among ADRs causing and occurring at admission (Figure 3).
About 30% of the 135 ADRs included at least one drug with
a PharmGKB CA associated with the ADR, suggesting that
these ADRs may have been at least partially predictable based
on patient genotype. Most of these drugs were chemothera-
peutic drugs, warfarin and clopidogrel, and many had a high
level of evidence (1A–2B) for the association with the re-
ported ADRs (Table 2).
Predictors of having ADRs at admission
We explored variables that were predictive of having an ADR
at the time of hospital admission. Among the significant var-
iables from univariate analysis (Table 1), four variables were
eliminated sequentially based on variance inflation factor
Figure 1
Characteristics of ADRs by causality, type, severity, avoidability and whether they caused admission. The figure shows the proportions of the 135
‘definite’ and ‘probable’ ADRs by causality, type, severity, avoidability and by whether they caused or simply occurred at admission. The distribu-
tion of ADRs by causality, type and avoidability were similar in ADRs that caused or occurred at admission. However, more ADRs causing admission
had a higher severity grade than those that occurred at admission (Fisher’s exact test P = 2.19 × 105)
Figure 2
Most common ADRs. The figure shows the number of ‘definite’ and ‘probable’ ADRs grouped by ADRs. GI ADRs included nausea, vomiting, ab-
dominal bloatedness, diarrhoea, constipation and dyspepsia. Electrolyte abnormalities included high or low serum sodium, potassium, magne-
sium, phosphate or calcium levels. *Acute gout flare, cytomegalovirus reactivation/viraemia, elevated creatine kinase, elevated haemoglobin,
elevated T4/suppressed thyroid stimulating hormone, extrapyramidal side effects, headache, elevated white cell count, lactic acidosis, mucositis,
peripheral neuropathy, premature ventricular complex, QTC prolongation, seizure and tremors (1 each). ADR: adverse drug reaction, GI: gastro-
intestinal, INR: international normalized ratio
S. L. Chan et al.
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(VIF) [having at least one drug with PharmGKB CA (level 1 or
2 evidence), being admitted to oncology specialty, the pro-
portion of drugs with PharmGKB CA (any level of evidence),
and having at least one drug with PharmGKB CA (level 1 evi-
dence)]. The remaining variables were entered into a stepwise
regression and the best set of predictors for having an ADR at
admission was place of admission (emergency department vs.
specialist outpatient clinics), ward type, having a CVS condi-
tion, having cancer and having at least one drug with
PharmGKB CA of any level of evidence (Table 3).
Discussion
Here we report the results of the first large prospective obser-
vational study of ADRs among the general hospitalized adult
population in Singapore. The key findings from this study are
that 12.4% of patients admitted to a large tertiary care hospi-
tal had an ADR, and that in 8.1% of hospital admissions, an
ADR contributed to the reason for hospitalization.
Previous studies examining ADRs causing hospital admis-
sion have reported rates of 2.7–8.8% of hospital admission to
be caused by ADRs [6, 7, 9, 10, 12]. Our finding that 8.1% of
admissions were caused at least in part by an ADR is therefore
consistent with these prior data. However, our finding that
12.4% of patients had an ADR at time of hospital admission
is higher than what has been reported previously, namely
2.3–7.9% [5, 16, 33, 34]. Several factors likely contribute to
this difference. Notably, patients in our study received a
larger number of drugs than was reported in previous studies
[34, 35]. An Italian study surveying patients admitted
through the emergency department to three hospitals found
an initial diagnosis of an ADR in 21.2% of patients but 98%
of those were deemed predictable and were not further
analysed, thus this prevalence could be overestimated, as
the causality of those ADRs were unknown [36]. Studies
which considered ADRs causing admission and focused on
medical wards and/or older patients tended to report a higher
prevalence of 3.3–12.8% [8, 11, 37–44], which is in line with
what we observed. Our choice of the causality assessment
tool might also have resulted in a higher prevalence com-
pared to other studies. Many previous ADR surveys have used
the Naranjo tool, but difficulties in answering some of the
questions in the tool may artificially lower the causality score,
thus reducing its sensitivity [23]. The LCAT is a modification
of the Naranjo tool designed to address these problems, and
its use in our study might have resulted in more ADRs being
classified as ‘definite’ and ‘probable’ than if we had used the
Naranjo tool.
Eleven ADRs were severe enough to warrant a higher
level of care, cause permanent disability or contribute to pa-
tient death. However, all but three ADRs were ‘definitely’ or
‘possibly’ avoidable, suggesting a considerable opportunity
to reduce healthcare burden and costs due to ADRs in
Singapore. Four of these 11 severe ADRs involved bleeding
due to warfarin or clopidogrel, highlighting the importance
of reducing this type of ADR. The high number of
‘avoidable’ ADRs should be interpreted with caution as it
could be partly an artefact of the avoidability scale used.
We chose the method of Hallas et al. [26] as it is commonly
used, but its validity and reliability relies heavily on the as-
sessors’ notion of ‘good medical practice’ and ‘obligatory
demands’ [45].
In terms of healthcare burden, patients with ADRs on
average stayed one day longer than those who did not, trans-
lating to about 9,400 extra hospital days per year at SGH.
Extrapolated to all of Singapore, this would be an additional
48 000 hospital days per year caused by ADRs.
It is noteworthy that almost a third of ADRs detected in
our study were caused by at least one drug with a PharmGKB
CA for that ADR, suggesting that at least part of these ADRs
could potentially be predicted or avoided using
pharmacogenomic testing. The most notable drug–ADR pair
Figure 3
Most common drugs causing ADRs. The figure shows the number of ADRs caused by drugs in each anatomical therapeutic drug class. The total
number exceeds 135 (total number of ‘definite’ and ‘probable’ ADRs) as an ADR can be counted more than once if the associated drugs fall under
different drug classes. *Miscellaneous: phosphate binders (5), resonium (1), vitamin D (1). ADR: adverse drug reaction
Prevalence of ADR-related hospitalization in Singapore
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with this potential is warfarin and bleeding and/or
supratherapeutic INR, for which there is very strong evidence
(PharmGKB CA level 1A–2A). Indeed, a recent meta-analysis
of randomized clinical trials showed that pharmacogenetic-
based dosing significantly reduced risk of adverse events
and major bleeding compared to conventional dosing [46].
Warfarin pharmacogenetic testing may therefore reduce
warfarin-related hospitalizations and their associated
healthcare burden. The other main group of drugs for which
ADRs might be predicted or prevented with
pharmacogenomic testing is the chemotherapeutic agents.
The strength of evidence, however, varies depending on the
specific drug–ADR pair (level 1A–3).
Apart from a third of ADRs actually having a pharmacoge-
netic association, 69% of all patients have at least one drug
with a level 1 or 2 PharmGKB CA (Table 1), suggesting amuch
higher potential for optimizing therapy and prevention of fu-
ture ADRs. This is in line with a study arguing the case for pre-
emptive pharmacogenomic testing, which reported that 65%
of patients in a medical centre would be exposed to at least
one drug with an established pharmacogenetic association
within a 5-year period [47]. At present, clinical utility has
only been demonstrated for a handful of drug–ADR pairs,
such as HLA-B*57:01 and abacavir hypersensitivity [48], and
HLA-B*15:02 and carbamazepine-induced SJS/TENS [19].
The clinical significance of other pharmacogenomic associa-
tions is less clear, and the recommended action in the pres-
ence of a risk allele is not always well established.
Nonetheless, the high percentage of ADR–drug pairs detected
in our study for which pharmacogenomic associations exist
suggests that at least a proportion of these ADRs could have
been in principle predicted using pharmacogenetic testing.
Future studies will be needed to determine the clinical benefit
and cost-effectiveness of pre-emptive pharmacogenomic test-
ing in Singapore.
In contrast to most studies in similar settings where the
most common ADR was bleeding [5–8, 11, 16, 34, 40–42],
the most common ADR in our study affected the GI system
(including nausea, vomiting, abdominal bloatedness, diar-
rhoea, constipation and dyspepsia). The reason for this is un-
clear but could be due to differences in recording of such
subjective symptoms and the threshold different researchers
have for considering these to be potential ADRs.
Nevertheless, bleeding was also one of the most common
ADRs, as these events were clinically significant and would
lead to an unplanned admission. Cumulatively, CVS drugs
contributed to the highest number of ADRs, consistent with
several prior studies [6, 9, 10, 37, 40, 42]. This could be due
to the fact that the clinical condition of the patients often
warranted several CVS drugs to be co-prescribed despite
their additive risk for ADRs, most commonly renal
impairment and electrolyte disturbances. Interestingly,
non-steroidal anti-inflammatory drugs were highlighted in
several previous studies [5, 6, 8, 16], but these drugs were
not a common cause of ADRs in our study.
Consistent with other studies [6–12, 16, 33, 37, 39, 40,
42–44], we found that patients with ADRs tended to be older,
were more likely to be admitted to a medical ward and re-
ceived more drugs. However, many variables including age
and number of drugs were eliminated in the final set of pre-
dictors because of collinearity with other variables. For exam-
ple, older patients, medical patients and patients with a CVS
condition tended to receive more drugs, and patients with
more drugs were more likely to have at least one of themwith
a PharmGKB CA (Supplementary information).
There are several strengths in our study. Firstly, this is the
first ADR survey in the Singapore general adult population,
an important population to study for the estimation of the
burden of clinically impactful ADRs. Compared to spontane-
ous reporting, which captured approximately 11 500 ADRs
from all Singapore public and private hospitals in 2014 [49],
we estimate the number of ADRs at the point of hospital ad-
mission alone in adults (not including those occurring during
admission) across Singapore to be about 54 000 [50].
Secondly, this was a prospective study, a design that allowed
the most complete and accurate capture of information
possible. Lastly, we have a relatively large sample size for
reasonably precise estimation of the prevalence of ADRs at
admission.
There are a number of limitations of this study that merit
consideration. Firstly, adjudication of a potential ADR was
dependent on clinical judgement. Patients often have
underlying conditions that may contribute to the presenting
complaint or finding and the role of the suspected drug(s)
can be difficult or impossible to establish. However, this is
an inherent limitation of any ADR survey, even prospective
ones. Therefore we employed independent observers who
were trained pharmacists and used validated instruments
Table 3
Factors associated with ADR at admission
Variable Odds ratio (95% CI) P-value
Admitted from SOC (vs. ED) 2.21 (1.33–3.59) 1.73 × 103
Medical ward (vs. surgical) 2.18 (1.22–4.20) 0.013
Have a CVS condition 2.58 (1.50–4.70) 1.03 × 103
Have cancer 1.87 (1.20–2.87) 4.88 × 103
Have at least one drug with a PharmGKB CA (any level of evidence) 6.64 (1.98–41.4) 0.010
This table shows the significant variables predicting having an ADR at admission after multivariate analysis
CI, confidence interval; CVS, cardiovascular; ED, emergency department; PharmGKB CA, Pharmacogenomics knowledgebase clinical annotation;
SOC, specialist outpatient clinics
Prevalence of ADR-related hospitalization in Singapore
Br J Clin Pharmacol (2016) 82 1636–1646 1643
to adjudicate the likelihood that a patient experienced an
ADR. Secondly, patients’ drug history may sometimes be in-
accurate due to compliance issues or self-medication. We
endeavoured to collect the most accurate information avail-
able using patients’ medical records and pharmacists’ medi-
cation reconciliation reports, which included interviews
with the patient and family members when necessary. An
additional limitation relates to the fact that our study was
conducted at a single centre. While we believe our data are
likely to be broadly representative of other tertiary medical
centres in Singapore, this would require additional valida-
tion in future studies. Nevertheless, our study took place at
the largest acute care hospital in Singapore and we believe
these findings are noteworthy to SGH and other healthcare
institutions in Singapore and beyond.
In conclusion,we found theprevalenceofADRs athospital
admission among adults in Singapore to be 12.4%, highlight-
ing a considerable potential for improvement in health
outcomes and healthcare burden. Our study has for the first
time quantified the burden of clinically impactful ADRs in
the general adult population and identified themost common
ADR types and drugs responsible, providing vital information
for targeted efforts in pharmacovigilance, patient education,
pharmacogenomic testing and future pharmacogenomic
research for reduction of ADR-related hospitalizations in
Singapore.
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